Protembis Closes €30M Series B Financing to Support ProtEmbo IDE Pivotal Trial

Aachen, Germany-based privately-held Protembis has closed €30 million Series B financing led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund, to support the enrollment of the Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816) of ProtEmbo, a catheter-based cerebral protection system to deflect embolic material away from the cerebrovascular circulation during leftsided heart procedures, in particular transcatheter aortic valve replacement (TAVR).

The new financing reflects the fact that the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement,” said Karl von Mangoldt and Conrad Rasmus Co-CEOs of Protembis.

As a long-term believer in the need to protect the brain from all new lesions during transcatheter aortic valve replacement, I am very pleased to join Protembis. The ProtEmbo System and the clinical trial design are both novel and I am confident that they will be highly disruptive to the field of cerebral embolic protection, removing or mitigating many of the current issues that concern the physician community,” said Keith D. Dawkins, MD, who joins Protembis Board of Directors with more than 35 years of experience in the cardiovascular environment.

Having such a visionary leader as Dr Dawkins join our Board of Directors is an exciting indication of the opportunities that cerebral embolic protection holds for future transcatheter therapies. We look forward to close collaboration as the field develops and our superiority trial gains momentum,” said Azin Parhizgar, PhD, Chairwoman of the Board of Directors.

To view the source version, please click HERE.

en_GBEnglish (UK)